2-methyl-thieno-benzodiazepine

• US 5,229,382 A
• Filed: 05/22/1992
• Issued: 07/20/1993
• Est. Priority Date: 04/25/1990
• Status: Expired due to Term

• Current Assignee: Lilly Industries Limited
• Original Assignee: Lilly Industries Limited
• Inventors: Chakrabarti, Jiban K., Tupper, David E., Hotten, Terrence M.
• Primary Examiner(s): Shah, Mukund J.
• Assistant Examiner(s): DATLOW, PHILIP I
• Application Number:
  US07/890,348
• Time in Patent Office: 424 Days
• Field of Search: 540/557, 514/220
• US Class Current: 514/220
• CPC Class Codes: C07D 333/38 Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• CPC Class Codes: C07D 495/04 Ortho-condensed systems

Abstract

2-Methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##

Claims

1. 2-Methyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof.

2. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof together with a pharmaceutically acceptable diluent or carrier therefor.

3. A pharmaceutical composition in capsule or tablet form comprising from 2.5 to 5 mg of the compound of claim 1 together with a pharmaceutically acceptable diluent or carrier therefor.

15. A pharmaceutical composition in capsule or tablet form comprising from 0.1 to 20 mg of the compound of claim 1 together with a pharmaceutically acceptable diluent or carrier therefor.

4. A method of treating an animal, including a human, suffering from or susceptible to psychosis, acute mania or mild anxiety states, which comprises administering an effective amount of 2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine, or a pharmaceutically acceptable acid addition salt thereof.

5. A method of claim 4 for treating an animal, including a human, suffering from or susceptible to psychosis.

6. A method of claim 5 wherein the effective amount is from 0.1 to 20 mg per day of 2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine, or a pharmaceutically acceptable acid addition salt thereof.

7. A method of claim 5 for treating an animal, including a human, suffering from or susceptible to schizophrenia.

8. A method of claim 7 wherein the effective amount is from 0.1 to 20 mg per day of 2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine, or a pharmaceutically acceptable acid addition solution salt thereof.

9. A method of claim 5 for treating an animal, including a human, suffering from or susceptible to schizophreniform diseases.

10. A method of claim 9 wherein the effective amount is from 0.1 to 20 mg per day of 2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine, or a pharmaceutically acceptable acid addition salt thereof.

11. A method of claim 4 for treating an animal, including a human, suffering from or susceptible to acute mania.

12. A method of claim 11 wherein the effective amount is from 0.1 to 20 mg per day of 2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine, or a pharmaceutically acceptable acid addition salt thereof.

13. A method of claim 4 for treating an animal, including a human, suffering from or susceptible to mild anxiety states.

14. A method of claim 13 wherein the effective amount is from 0.1 to 20 mg per day of 2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine, or a pharmaceutically acceptable acid addition salt thereof.